Obermeyer Wealth Partners Has $7.16 Million Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• Obermeyer Wealth Partners cut its stake in Novo Nordisk by 64.2% in Q4, selling 252,523 shares and ending the period with 140,797 shares worth $7.164 million.
• Novo Nordisk beat quarterly estimates with $1.01 EPS vs. $0.90 expected and revenue of $12.43 billion, reporting a 33.03% net margin and strong return on equity.
• Positive product news—an oral semaglutide pediatric trial met its main goal—helped lift the stock (shares were up ~6.9%), but analyst sentiment is mixed with a consensus rating of "Hold" and a $65.56 average price target.

Obermeyer Wealth Partners decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 64.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 140,797 shares of the company's stock after selling 252,523 shares during the period. Obermeyer Wealth Partners' holdings in Novo Nordisk A/S were worth $7,164,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. TBH Global Asset Management LLC increased its position in shares of Novo Nordisk A/S by 5.6% during the fourth quarter. TBH Global Asset Management LLC now owns 9,065 shares of the company's stock worth $461,000 after acquiring an additional 479 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $509,000. Directional Asset Management bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $481,000. Rakuten Securities Inc. increased its position in shares of Novo Nordisk A/S by 23.8% during the fourth quarter. Rakuten Securities Inc. now owns 12,252 shares of the company's stock worth $623,000 after acquiring an additional 2,357 shares in the last quarter. Finally, Diversified Enterprises LLC increased its position in shares of Novo Nordisk A/S by 21.3% during the fourth quarter. Diversified Enterprises LLC now owns 7,902 shares of the company's stock worth $402,000 after acquiring an additional 1,386 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 6.9%

Shares of NVO stock opened at $41.19 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The firm's fifty day moving average price is $39.13 and its two-hundred day moving average price is $47.81. The firm has a market capitalization of $183.93 billion, a P/E ratio of 11.87, a PEG ratio of 9.17 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. On average, equities analysts predict that Novo Nordisk A/S will post 3.34 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were paid a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date was Monday, March 30th. Novo Nordisk A/S's payout ratio is presently 50.43%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage pediatric trial win — oral semaglutide met its main goal in 10–17 year olds with type 2 diabetes, supporting a planned U.S. launch and expanding addressable market for an oral GLP‑1 in youth. Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Market reaction to trial news — outlets report NVO shares rising after the pediatric oral semaglutide data, indicating investor enthusiasm for incremental product launches and revenue growth. Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
• Positive Sentiment: Competitive edge in obesity market — early prescription data show Lilly’s new obesity treatment trailing Novo’s Wegovy, pressuring Lilly shares and reinforcing Novo’s market leadership in weight‑loss drugs. Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy
• Positive Sentiment: Short interest fell sharply — short interest declined ~14.6% in April to ~17.0M shares (0.4% of float), lowering potential short‑squeeze risk and signaling reduced bearish positioning. (internal short‑interest data)
• Neutral Sentiment: Valuation/price discussion — analysts and commentators are parsing whether current pricing reflects recent share weakness and longer‑term growth prospects; this keeps the stock sensitive to further data and guidance. Is Novo Nordisk NYSE: NVO Pricing Reflect Its Recent Share Slump And Growth Outlook
• Negative Sentiment: Analyst target trimmed — Citigroup cut its price target (DKK 309 → DKK 275) while keeping a neutral rating, a reminder of lingering valuation concerns that could cap upside. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Recent short‑term pullbacks — coverage noted a recent session where NVO closed lower, highlighting that momentum can reverse on macro or sector weakness. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market

Analysts Set New Price Targets

NVO has been the subject of several research reports. TD Cowen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price objective for the company. in a research report on Tuesday, March 10th. BMO Capital Markets reissued a "market perform" rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an "outperform" rating and a $175.00 price objective for the company. Weiss Ratings downgraded shares of Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price objective for the company in a research report on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.